BPC-157/TB-500 20MG

Description

BPC-157/TB-500 20mg blend — research peptide, Canada

Researched & reviewed by the SPO Quality Team · Last reviewed: 30 September 2026

Two peptides with separate histories share this 20mg vial. BPC-157 is a fifteen-residue fragment of a gastric-juice protein whose rat liver-injury studies date from 1993^[1]; TB-500 is a trade name that has covered both thymosin β4 — the 43-residue actin-sequestering protein sequenced in 1981^[5] — and its acetylated seven-residue core, Ac-LKKTETQ^[8]. Laboratories buy a co-formulated vial for method development that must resolve two peptides in one sample, or for side-by-side comparison against the single-compound vials. Almost every study of either compound tested it alone; the one experiment that combined them found no advantage in doing so^[9]. This is lyophilized research-grade material for laboratory use only.

Full research overviews, study tables & references → BPC-157 research guide · TB-500 research guide

Identity at a glance

Batch documentation

A batch-specific COA for this strength has not been posted yet — see the COA library (/coa/). The Testides report in the library (JWAY-BPCTB-10-062226) belongs to the 10mg blend; its masses, ratio and purity describe that batch and are deliberately not reproduced here. A useful 20 mg report would give the total mass, each component’s mass, an HPLC purity figure and a mass-spectrometry line that settles which TB-500 form is present (4963 Da or 889 Da).

What researchers have looked at

• BPC-157 — rat liver (1993): the fragment prevented necrosis or fatty change after bile-duct plus hepatic-artery ligation, restraint stress and carbon tetrachloride, where bromocriptine, amantadine and somatostatin did little^[1].
• BPC-157 — rat tendon cells (2011, 2014): faster outgrowth from Achilles-tendon explants and better fibroblast survival under stress without a direct effect on proliferation^[2]; growth-hormone-receptor expression rose dose- and time-dependently in tendon fibroblasts^[3].
• Thymosin β4 — mouse heart (2004, 2007): the peptide formed a complex with PINCH and integrin-linked kinase, activated Akt and improved cardiac repair after coronary ligation^[6]; it mobilised adult epicardial progenitors and drove new vessel formation^[7].
• TB-500 — equine doping control (2012): the marketed preparation’s key ingredient was N-acetyl-LKKTETQ, and a liquid-chromatography–mass-spectrometry method was built to detect it and its metabolites in horse urine and plasma^[8].
• The combination — rat Achilles tendon (2026, 32 rats): TB-500 alone reached statistical significance on histology where BPC-157 alone did not; giving both together produced no additional benefit over either^[9].
• Limits (2026 review): BPC-157 has no approved formulation, no validated regimen and no completed Phase II trial^[4].

Those are literature findings about the components in the models named. They are not properties of this vial, and no benefit is claimed for the material sold.

Storage and handling

• Sealed vial at −20 °C for long-term storage (the site states up to 24 months as lyophilized powder); cool, dry and dark for short holds; avoid freeze–thaw cycling.
• A two-peptide solution has two stabilities: thymosin β4 carries an oxidisable methionine, and both peptides are less stable dissolved than dry. Make up only what an experiment needs. How to reconstitute or handle it is the researcher’s call and is not described here.

Also listed: BPC-157/TB-500 10MG (posted COA) · BPC-157 5MG · BPC-157 10MG · TB-500 5MG · TB-500 10MG. Orders ship from inside Canada by Canada Post; the shipping policy has dispatch cut-off, delivery times and the free-shipping threshold. The full range is on the page where you can buy peptides online in Canada.

Frequently asked questions

Can I buy the BPC-157/TB-500 20mg blend in Canada?

Yes. Shop Peptides Online supplies the 20mg co-formulated vial as research-grade lyophilized material and ships it from inside Canada by Canada Post. Laboratory research only; neither component has an approved drug form.

Is there a COA for the 20mg blend?

Not yet for this strength. The COA library holds a Testides report for the 10mg blend (JWAY-BPCTB-10-062226); it describes that batch only and is not evidence for the 20 mg vial, so it is not shown here. A 20 mg batch report will be embedded when one is issued.

Which form of TB-500 is in the blend?

‘TB-500’ is a trade name that has been applied both to full-length thymosin β4 (43 residues, ~4963 Da) and to its acetylated 17–23 fragment Ac-LKKTETQ (~889 Da). Without a batch report for this vial, the form cannot be stated; a future report’s mass-spectrometry line is the only way to tell them apart.

Is the BPC-157/TB-500 blend for human use?

No. It is research-grade material for laboratory use only, not for human or animal consumption. BPC-157 has no approved formulation and no completed Phase II trial (PMID 42198317); TB-500 is a veterinary grey-market preparation studied for doping control (PMID 23084823); the only study combining the two found no added benefit (PMID 42542926); and Shop Peptides Online provides no dosing or administration guidance.

References

1. Sikiric P, Seiwerth S et al. (1993). Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. Life Sci. PMID 7901724
2. Chang CH, Tsai WC et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). PMID 21030672
3. Chang CH, Tsai WC et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. PMID 25415472
4. Mateescu DM, Gavrilescu DM et al. (2026). BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. PMID 42198317
5. Low TL, Hu SK et al. (1981). Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A. PMID 6940133
6. Bock-Marquette I, Saxena A et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. PMID 15565145
7. Smart N, Risebro CA et al. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. PMID 17108969
8. Ho EN, Kwok WH et al. (2012). Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. PMID 23084823
9. Biçer O, Adanir O et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. PMID 42542926

For laboratory research use only; not for human or animal consumption. This description identifies the two components, their documentation status and their published literature, and makes no claim of efficacy or safety for the material sold.